 |
|
| Clinical Trials |
|
Research  Clinical Trials |
|
|
| Our physicians are actively involved in a in a variety of institutional and multi-center clinical trials. We have listed below several trials that are currently or will soon be enrolling patients. We encourage our patients and referring physicians to read the brief clinical trial descriptions below and click on "Consent Form" to obtain the full details of our trials. |
| PDF Documents |
| View the PDF documents on this page with the FREE Adobe Acrobat Reader. Download now. |
|
|
| The consent forms are printable for review at your convenience. Should you feel you would like to learn more about these trials, please contact the appropriate physician or research coordinator listed below. We thank you for your time and interest in our clinical research activities. |
| |
| Current Clinical Trials | |
|
| UCSF Mt. Zion Center for Inflammatory Bowel Disease |
|
|
VISILIZUMAB:
For severe colitis. Eligible patients must have steroid refractory ulcerative colitis. | |  View Consent Form |
|
ADACOLUMN Apheresis System:
For moderate to severe ulcerative colitis patients. | | View Consent Form |
|
LEUKINE:
For treatment of active Crohn's disease. | | View Consent Form |
|
ANTEGREN:
Safety and efficacy of Antegren in patients with moderate to severe Crohn's disease whose C-Reactive Protein is elevated. | | |
|
If you are interested in hearing more about these trials, please contact:
Yelena Idomsky at 415-353-7871 |
| | |
| UCSF Parnassus - Bariatric Surgery Research Program | | |
|
|
| A Study to Examine The Effect Of Weight Loss On Clinical, Biochemical And Liver Biopsy Features And Examination Of Potential Biochemical And Genetic Factors In the Causation and Progression/Regression of Fatty Liver Disease | | View Consent Form |
|
| The purpose of this study is to better understand the consequences of bariatric surgery (weight loss surgery) on fatty liver disease, a common and potentially serious liver disease in obese patients, that is frequently present but unsuspected. Fatty liver disease is best detected by obtaining a small sample of liver (liver biopsy) to accurately determine the presence and extent of liver injury. After bariatric surgery, it is anticipated that the patient will lose a considerable amount of body weight. However, the effect of this weight loss on fatty liver disease is uncertain, i.e., does the liver disease improve, remain unchanged or get worse. The best way to determine the effect of the anticipated weight loss on fatty liver disease is through a liver biopsy performed initially by the surgeon (Dr. Marco Patti) during bariatric surgery and if abnormal, repeated one year later as an outpatient through a simple non-surgical procedure (by Dr. Raphael Merriman, Specialist in Liver Disease). Blood is also drawn for other analyses. |
|
If you are interested in hearing more about this study, please contact:
Dr. Raphael Merriman at 415-514-2860 or email at raphael@itsa.ucsf.edu |
| | |
|
|
|
